Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Nat Chem Biol. 2020 Jul 21;16(8):817–825. doi: 10.1038/s41589-020-0596-8

Fig. 2 |. overcoming resistance by designing inhibitors with distinct binding modes.

Fig. 2 |

a–e, Structural models of ALK kinase alleles in complex with crizotinib (a, ALK-WT, PDB: 2XP2; e, ALK-C116Y-L1198F, PDB: 5AAB), ceritinib (b, ALK-WT, PDB: 4MKC) and lorlatinib (c,d, ALK-C1156Y, PDB: 5A9U). Selected residues are indicated (stick representation).